Clinical Trials

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04283669 2026-03-13

NF110

12 enrolled 5 charts

CNS

Neurofibromatosis 2

NCT04693468 2026-03-13

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Phase 1 Recruiting

111 enrolled

Neoplasm Metastasis

NCT03620643 2025-10-30

ROLo

33 enrolled 13 charts

BreastGastrointestinal

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Phase 2 Terminated

40 enrolled

Gynecologic

Endometrial Cancer Recurrent

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

Rare Tumor

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04084717 2024-07-16

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02034981 2024-02-28

AcSé

246 enrolled

Phase 3 Not yet recruiting

Neoplasm Metastasis

NCT06254599 2024-02-12

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

255 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

34 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT01744652 2023-06-07

Dasatinib and Crizotinib in Advanced Cancer

62 enrolled

Neoplasm Metastasis

NCT02419287 2023-03-06

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

12 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02183870 2022-06-16

EUCROSS

34 enrolled

Adenocarcinoma, Lung Neoplasms

NCT02270034 2022-03-10

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

38 enrolled

CNS

Glioblastoma

NCT03088930 2022-02-11

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

3 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

24 enrolled

Genitourinary

Castration-resistant Prostate Cancer

NCT01548144 2021-09-13

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Phase 1 Terminated

178 enrolled

Advanced Cancers

NCT02510001 2021-07-13

MErCuRIC1

82 enrolled 36 charts

Gastrointestinal

Colorectal Neoplasms

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

96 enrolled

Lung Neoplasms, Recurrence

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01579994 2020-12-30

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

13 enrolled

Adenocarcinoma, Neoplasm Metastasis

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

90 enrolled

Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT01644773 2019-03-22

Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03874273 2019-03-14

Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

Phase 2/3 Unknown

25 enrolled

Plasma cell

Granuloma, Plasma Cell

NCT02142036 2019-03-13

MetAction

50 enrolled

Neoplasm Metastasis

NCT02836847 2018-05-07

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

152 enrolled

Gastrointestinal

Gallbladder Neoplasms

NCT01998126 2018-04-02

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

14 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02499614 2017-10-25

METROS

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02074878 2017-08-09

CRIZENT

Phase 1 Terminated

3 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02435108 2017-02-17

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

2 enrolled

Lymphoid

Lymphoma, Follicular

NCT02487316 2016-12-30

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Phase 4 Withdrawn

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02946359 2016-11-02

A+C in Metastatic Lung Adenocarcinoma Cancer

Phase EARLY_PHASE1 Withdrawn

60 enrolled

Lung Adenocarcinoma Metastatic

NCT02277457 2016-06-24

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations